Apalutamide Tablets (Erleada) is an androgen receptor inhibitor approved by the U.S. FDA, mainly indicated for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). As a strictly regulated prescription drug, patients must pay close attention to its purchasing process and usage specifications.
How to Purchase Apalutamide Tablets (Erleada)
Overseas Purchase
Patients may choose to consult and purchase the drug at hospital pharmacies or authorized pharmacies in countries or regions where Apalutamide has been launched.
Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.
Purchase through Medical Service Institutions
Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.
These institutions can usually provide legal import channels and offer professional consultation and guidance.
Important Preparations Before Purchasing Apalutamide Tablets (Erleada)
Strictly Follow the Medication Guidelines
The recommended dose of Apalutamide is 240 mg orally once daily, which can be administered as one 240 mg tablet or four 60 mg tablets.
The tablets should be swallowed whole; they must not be crushed or split. They can be taken with or without food.
Confirmation of Supporting Treatment Regimens
Patients should concurrently receive gonadotropin-releasing hormone (GnRH) analog therapy, or have undergone bilateral orchiectomy.
These supporting treatments need to be continued throughout the entire course of Apalutamide treatment.
Assessment and Management of Fracture Risk
Apalutamide treatment may cause fractures in patients. Patients' fracture risk should be assessed, and those at risk of fractures should be monitored and managed in accordance with established treatment guidelines. The use of bone-targeted agents may also be considered.
Prevention of Fall Risk
Patients receiving Apalutamide treatment have an increased incidence of falls, which is particularly prominent in elderly patients.
Patients' fall risk should be assessed, and corresponding preventive measures should be taken.
Methods to Identify the Authenticity of Apalutamide Tablets (Erleada)
Verify the Characteristics of Drug Packaging
240 mg tablets: Bluish-gray to gray, oval film-coated tablets, with "E240" embossed on one side.
60 mg tablets: Light yellow to grayish-green, oblong film-coated tablets, with "AR60" embossed on one side.
Check the Physical Properties of the Drug
Authentic tablets should be intact without cracks, discoloration, or other abnormalities.
The size, color, and embossed text of the tablets must be completely consistent with the official instructions.
Confirm the Manufacturer's Information
By verifying the manufacturer's information on the drug packaging, confirm that the drug is manufactured by Janssen Products, LP. Relevant information can also be verified through official channels.
